Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

Dr. Musunuru and Dr. Ahrens-Nicklas holding KJ post infusion Senior Correspondent Gene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments ...

CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...

For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient ...

Bill Whitaker is an award-winning journalist and 60 Minutes correspondent who has covered major news stories, domestically and across the globe, for more than four decades with CBS News. America's ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions-but there is always room for improvement. A new paper by investigators from Mass General Brigham ...